Experimental Hematology and Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma
ConclusionsThis study highlights the importance of ASAP2 in sustaining c-MET signaling, which can facilitate HCC progression. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - April 15, 2023 Category: Cancer & Oncology Source Type: research

Wdr5 is essential for fetal erythropoiesis and hematopoiesis
AbstractWDR5 is a highly conserved protein that performs multiple scaffolding functions in the context of chromatin. However, efforts to understand the function of WDR5 in normal tissues physiologically are quite limited so far. In our study, we explored the function of Wdr5 in erythropoiesis and hematopoiesis by using a hematopoietic-specificWdr5 knockout mouse model. We found that loss ofWdr5 mediated byVav-iCre leads to embryonic lethality with defective erythropoiesis. In addition, Wdr5-deficiency completely impairs the hematopoietic stem and progenitor cells function and might alter the immunophenotype of these st...
Source: Experimental Hematology and Oncology - April 15, 2023 Category: Cancer & Oncology Source Type: research

Comparison of local ablative therapies, including radiofrequency ablation, microwave ablation, stereotactic ablative radiotherapy, and particle radiotherapy, for inoperable hepatocellular carcinoma: a systematic review and meta-analysis
AbstractSurgical intervention is the first-line treatment in well-selected hepatocellular carcinoma (HCC) patients. However, only a few patients are suitable to receive radical surgery. We conducted a systematic review and meta-analysis to evaluate local control among four local ablative therapies in inoperable HCC patients, including radiofrequency ablation therapy (RFA), microwave ablation therapy (MWA), stereotactic ablative radiotherapy (SABR), and particle radiotherapy. The primary outcome was the local control rate and the secondary were regional and distant progression rates, overall survival rate, and adverse event...
Source: Experimental Hematology and Oncology - April 12, 2023 Category: Cancer & Oncology Source Type: research

Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients
In conclusion, DAC in combination with the FC lymphod epletion regimen may be a new treatment option that can improve the efficacy of CAR T-cell therapy in r/r B-ALL. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - April 10, 2023 Category: Cancer & Oncology Source Type: research

Surface TREM2 on circulating M-MDSCs as a novel prognostic factor for adults with treatment-na ïve diffuse large B-cell lymphoma
ConclusionIn treatment-na ïve DLBCL adults, a high surface-TREM2 level on circulating M-MDSCs is a poor prognostic factor for both PFS and OS and warrants further investigation for its potential as a novel target in immunotherapy. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - April 7, 2023 Category: Cancer & Oncology Source Type: research

Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy
AbstractTumor development relies on a complex and aberrant tissue environment in which cancer cells receive the necessary nutrients for growth, survive through immune escape, and acquire mesenchymal properties that mediate invasion and metastasis. Stromal cells and soluble mediators in the tumor microenvironment (TME) exhibit characteristic anti-inflammatory and protumorigenic activities. Ubiquitination, which is an essential and reversible posttranscriptional modification, plays a vital role in modulating the stability, activity and localization of modified proteins through an enzymatic cascade. This review was motivated ...
Source: Experimental Hematology and Oncology - March 30, 2023 Category: Cancer & Oncology Source Type: research

The clinical impact of IKZF1 mutation in acute myeloid leukemia
AbstractGenetic heterogeneity poses a great challenge to the understanding and management of acute myeloid leukemia (AML). Knowledge of theIKZF1 mutation in AML specifically is extremely limited. In a previous work, we described the distribution pattern ofIKZF1 mutation in AML, but its clinical impact has remained undefined due to the limited number of cases. Herein, we attempt to answer this question in one relatively large cohort covering 522 newly diagnosed AML patients. A total of 26IKZF1 mutations were found in 20 AML patients (20/522, 3.83%). This condition has a young median age of onset of morbidity (P = 0.032...
Source: Experimental Hematology and Oncology - March 30, 2023 Category: Cancer & Oncology Source Type: research

PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma
AbstractPrimary mediastinal (thymic) large B-cell lymphoma (PMBCL) is a rare, aggressive subtype of non-Hodgkin lymphoma and has a complex inflammatory microenvironment. Although most patients can be cured with standard-of-care immunochemotherapy, patients who have disease relapse have an unfavorable prognosis. Pre-treatment prognostic biomarkers in PMBCL are needed. In this retrospective study, we analyzed the clinical features and outcomes of PMBCL patients and their association with immune cell subpopulations identified by multiplex immunofluorescence at initial diagnosis. Two different antibody panels were used to asse...
Source: Experimental Hematology and Oncology - March 20, 2023 Category: Cancer & Oncology Source Type: research